Absci Corporation (ABSI), based in Vancouver, Washington, is a biotechnology company with a bold mission: to revolutionise drug discovery using artificial intelligence (AI) and advanced lab techniques.
Their innovative approach combines technology and science to create new protein-based drugs faster and more efficiently.
Let’s explore what makes Absci stand out and why it’s a company to watch.
Absci Video Overview
What Does Absci Do?
Absci’s Integrated Drug Creation platform aims to speed up the development of biologic medicines.
This system optimises multiple drug characteristics at once, helping bring effective treatments to patients more quickly.
The company’s current focus includes developing promising drug candidates:
- ABS-101 for inflammatory bowel disease.
- ABS-201 for hair loss.
- ABS-301 for solid tumors.
While these drugs target significant medical needs, they are still in early stages, undergoing preclinical and early clinical trials.
Absci’s Collaborations and Partnerships
Absci works closely with leading pharmaceutical and biotech companies to create next-generation protein-based drugs. Some of their key collaborations include:
- Memorial Sloan Kettering Cancer Center: Discovering new therapeutics using AI.
- AstraZeneca: Focusing on AI-driven drug discovery in oncology.
- Twist Bioscience: Designing novel therapeutics.
Recently, Absci teamed up with Owkin, a tech company specialising in predictive AI for drug development.
This partnership combines Absci’s expertise in designing antibodies with Owkin’s AI tools to identify and validate drug targets.
Their goal is to create innovative treatments for diseases like cancer and inflammation, streamlining the process from research to clinical trials.
Absci Gets A Massive Boost from AMD
Absci also secured a $20 million investment from AMD, one of the leading major tech companies.
This funding will help Absci develop antibody therapeutics using AMD’s high-performance chips and software.
It’s worth noting that this marks AMD’s first venture into healthcare.
The collaboration could reduce costs and speed up innovation cycles in drug discovery.
AMD’s investment not only strengthens Absci’s financial position but also highlights the growing role of AI in healthcare.
By leveraging AI and synthetic biology, Absci can design and test drug candidates within just six weeks, significantly accelerating the traditional drug development timeline.
Financial Performance and Risks
As of Q3 2024, Absci reported:
- Revenue: $1.7 million, up from $0.7 million in the same period in 2023.
- R&D Expenses: $18.0 million, reflecting increased lab operations and costs for advancing ABS-101.
- Net Loss: $27.4 million, compared to $22.0 million in Q3 2023.
- Cash Reserves: $127.1 million, projected to support operations into the first half of 2027.
While the company shows incredible potential, it faces high risks.
Drug development is a lengthy and expensive process, and Absci’s success hinges on bringing its drug candidates to market and fully integrating AI into its platform.
Technical Analysis
Absci’s stock has been volatile, with a 52-week range between $1.11 and $31.53 and a beta value of 2.19, indicating high sensitivity to market movements and volatility.
On the technical side:
- Daily Chart: The future cloud is bearish but thin, with candlesticks below the cloud.
- RSI: Currently at 44.16, showing a consolidating trend.
For those considering adding Absci stock to their portfolio, here are some suggested Buy Limit entry points:
- $2.80,
- $2.68
- $2.56
Investors may consider these levels for potential entry points, depending on their risk tolerance and investment goals. Remember: Investing is personal, and what is right for me might not be right for you. Always do your own due diligence. You should ONLY invest based on your own risk tolerance and your timeframe for reaching your portfolio goals.
Final Thoughts on Absci Corporation Stock:
Absci Corporation is at the forefront of integrating AI with biotechnology to transform drug discovery. While its innovative approach and strategic partnerships are promising, the company’s early-stage development and high risks make it a speculative investment.
For those willing to take the risk, Absci could be a game-changer in the biotech space. It is worth keeping an eye on its progress as it continues to push the boundaries of science and technology.
Are You Ready to Learn How to Successfully Compound Your Investments?
Do you want to learn how to analyse assets that align with your unique risk tolerance and financial goals? Are you interested in mastering the proven 5-Step Invest Diva Diamond Analysis strategy and the Triple Compounding™ method I use?
Register for your FREE Triple Compounding™ Training HERE AND get Kiana’s Triple Compounding™ workbook and personal risk management toolkit for FREE. Both available at no cost to you.
If you enjoyed my blog post about Absci Corporation Stock, you’ll love my post on ‘Upstart’s Stock Price Analysis.’
Disclosure: I am not a financial advisor and this is not financial advice. This information is for educational purposes only. This post about ‘Absci Corporation Stock’ may contain affiliate links, meaning I get a commission if you decide to make a purchase through my links, at no cost to you. Please see terms of service page for more information.
Grace provides Premium Coaching Services for Invest Diva. This includes delivering live weekly coaching sessions and analysis for members of the Invest Diva Premium Investing Group. Grace is a $100K Diva Award Winner | Entrepreneur, Investor & Content Creator. Starting from only $500 she built a six-figure portfolio with zero prior knowledge and experience using education from Invest Divas Triple Compounding Course.
